| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $370,038 | 11 | 100 |
Sells | $0 | 0 | 0 |
| Durso Jerome Benedict | director | 4 | $213,709 | 0 | $0 | $213,709 |
| GILL JOHN | director | 2 | $82,600 | 0 | $0 | $82,600 |
| WEAVER GREGORY L | Chief Financial Officer | 2 | $49,199 | 0 | $0 | $49,199 |
| Pisano Wayne | director | 1 | $20,410 | 0 | $0 | $20,410 |
| Sohn Catherine A. | director | 1 | $2,118 | 0 | $0 | $2,118 |
| Jorkasky Diane | director | 1 | $2,003 | 0 | $0 | $2,003 |
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This …
Over the last 12 months, insiders at Altimmune, Inc. have bought $370,038 and sold $0 worth of Altimmune, Inc. stock.
On average, over the past 5 years, insiders at Altimmune, Inc. have bought $141,463 and sold $715,422 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Durso Jerome Benedict (director) — $213,709. GILL JOHN (director) — $82,600. WEAVER GREGORY L (Chief Financial Officer) — $49,199.
The last purchase of 15,000 shares for transaction amount of $44,250 was made by Durso Jerome Benedict (President and CEO) on 2026‑08‑13.
| 2026-08-13 | Durso Jerome Benedict | President and CEO | 15,000 0.0079% | $2.95 | $44,250 | +3.13% | ||
| 2026-04-06 | GILL JOHN | director | 9,200 0.0107% | $3.41 | $31,350 | -11.11% | ||
| 2026-04-01 | Durso Jerome Benedict | President and CEO | 15,000 0.0171% | $3.14 | $47,100 | -5.13% | ||
| 2026-04-01 | WEAVER GREGORY L | Chief Financial Officer | 10,000 0.0114% | $3.15 | $31,499 | -5.13% | ||
| 2026-03-06 | Durso Jerome Benedict | President and CEO | 20,000 0.0227% | $3.54 | $70,790 | -15.25% | ||
| 2026-03-06 | WEAVER GREGORY L | Chief Financial Officer | 5,000 0.0057% | $3.54 | $17,700 | -15.25% | ||
| 2026-01-08 | Pisano Wayne | director | 5,000 0.0057% | $4.08 | $20,410 | -24.63% | ||
| 2026-01-05 | Sohn Catherine A. | director | 500 0.0007% | $4.24 | $2,118 | -24.69% | ||
| 2025-12-29 | Jorkasky Diane | director | 527 0.0006% | $3.80 | $2,003 | -16.30% | ||
| 2025-12-23 | GILL JOHN | director | 12,500 0.014% | $4.10 | $51,250 | -22.75% | ||
| 2025-12-22 | Durso Jerome Benedict | director | 12,500 0.0141% | $4.13 | $51,569 | -25.36% | ||
| 2025-03-17 | Sohn Catherine A. | director | 1,000 0.0013% | $5.78 | $5,785 | -28.98% | ||
| 2025-03-13 | WEAVER GREGORY L | Chief Financial Officer | 10,000 0.013% | $5.20 | $51,996 | -18.08% | ||
| 2024-08-19 | Sale | Drutz David | director | 16,011 0.0206% | $6.90 | $110,547 | -15.98% | |
| 2023-08-15 | Drutz David | director | 300 0.0006% | $2.88 | $863 | +145.20% | ||
| 2023-03-24 | Eisenstadt Richard I | Chief Financial Officer | 10,000 0.0213% | $4.31 | $43,140 | -5.32% | ||
| 2023-03-23 | Harris Matthew Scott | Chief Medical Officer | 10,000 0.0215% | $4.22 | $42,200 | -2.39% | ||
| 2023-03-23 | Drutz David | director | 9,000 0.0195% | $4.27 | $38,430 | -2.39% | ||
| 2022-12-22 | Sale | Pisano Wayne | director | 20,000 0.0383% | $15.01 | $300,268 | -73.88% | |
| 2022-08-30 | Sale | Garg Vipin K | President and CEO | 20,000 0.0429% | $20.02 | $400,322 | -47.31% |
| Durso Jerome Benedict | President and CEO | 62500 0.0321% | $127,500.00 | 4 | 0 | |
| WEAVER GREGORY L | Chief Financial Officer | 38078 0.0196% | $77,679.12 | 3 | 0 | |
| GILL JOHN | director | 21700 0.0112% | $44,268.00 | 3 | 2 | <0.0001% |
| Pisano Wayne | director | 13498 0.0069% | $27,535.92 | 2 | 2 | <0.0001% |
| Sohn Catherine A. | director | 1500 0.0008% | $3,060.00 | 2 | 0 | |
| Jorkasky Diane | director | 527 0.0003% | $1,075.08 | 1 | 1 | |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 6626403 3.4066% | $13.52M | 1 | 3 | |
| EVNIN LUKE | 10 percent owner | 6347614 3.2633% | $12.95M | 2 | 0 | |
| MPM BIOVENTURES III LLC | 10 percent owner | 6347614 3.2633% | $12.95M | 2 | 0 | |
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4500000 2.3134% | $9.18M | 4 | 0 | +64.5% |
| SCHAFFER DERACE L | director | 589453 0.303% | $1.2M | 41 | 5 | <0.0001% |
| KINLEY MATTHEW P | 541000 0.2781% | $1.1M | 11 | 0 | ||
| WRIGHT DAVID P | President and CEO | 399500 0.2054% | $814,980.00 | 8 | 0 | |
| PAPPAJOHN JOHN | director | 394044 0.2026% | $803,849.76 | 15 | 3 | |
| Enright William | President and CEO | 365839 0.1881% | $746,311.56 | 1 | 0 | <0.0001% |
| HEALTHCARE VENTURES VII LP | 10 percent owner | 250000 0.1285% | $510,000.00 | 1 | 0 | |
| Garg Vipin K | President and CEO | 236797 0.1217% | $483,065.88 | 1 | 2 | |
| RICHMAN ERIC I | director | 176822 0.0909% | $360,716.88 | 2 | 3 | |
| Drutz David | director | 41958 0.0216% | $85,594.32 | 6 | 1 | +43.65% |
| Harris Matthew Scott | Chief Medical Officer | 33311 0.0171% | $67,954.44 | 1 | 2 | <0.0001% |
| SAYARE MITCHEL | director | 32650 0.0168% | $66,606.00 | 2 | 0 | <0.0001% |
| CHANG LINDA L | SVP, CFO & Secretary | 30000 0.0154% | $61,200.00 | 1 | 1 | |
| St Peter Steven | director | 25000 0.0129% | $51,000.00 | 1 | 0 | |
| Eisenstadt Richard I | Chief Financial Officer | 22010 0.0113% | $44,900.40 | 1 | 0 | <0.0001% |
| Runge Jeffrey W. | director | 20000 0.0103% | $40,800.00 | 2 | 0 | |
| FUERST THOMAS RICHARD | SVP, Chief Scientific Officer | 15000 0.0077% | $30,600.00 | 2 | 0 | |
| Karp Jordan P | SVP, General Counsel | 10000 0.0051% | $20,400.00 | 1 | 0 | |
| Schafer Klaus | director | 8900 0.0046% | $18,156.00 | 1 | 1 | +5.5% |
| Roberts M Scot | Chief Scientific Officer | 8305 0.0043% | $16,942.20 | 1 | 3 | <0.0001% |
| Price Kevin | President-Pharmathene UK, Ltd. | 2500 0.0013% | $5,100.00 | 1 | 0 |
$3,887,391 | 114 | 13.01% | $433.37M | |
$31,123,523 | 108 | 6.46% | $387.86M | |
Altimmune, Inc. (ALT) | $24,384,691 | 42 | -30.27% | $396.82M |
$2,481,409 | 33 | 201.68% | $455.48M | |
$50,191,994 | 27 | 106.80% | $466.61M |
| Increased Positions | 124 | +89.86% | 17M | +41.72% |
| Decreased Positions | 53 | -38.41% | 4M | -9.55% |
| New Positions | 48 | New | 3M | New |
| Sold Out Positions | 23 | Sold Out | 1M | Sold Out |
| Total Postitions | 209 | +51.45% | 55M | +32.17% |
| Vanguard Group Inc | $22,371.00 | 6.13% | 6.37M | +1M | +23.35% | 2025-09-30 |
| Blackrock, Inc. | $22,370.00 | 6.13% | 6.37M | +699 | +0.01% | 2025-09-30 |
| State Street Corp | $12,640.00 | 3.46% | 3.6M | +847,617 | +30.78% | 2025-09-30 |
| Tang Capital Management Llc | $7,481.00 | 2.05% | 2.13M | -618,693 | -22.5% | 2025-09-30 |
| Geode Capital Management, Llc | $7,081.00 | 1.94% | 2.02M | +82,505 | +4.26% | 2025-09-30 |
| Two Sigma Investments, Lp | $7,009.00 | 1.92% | 2M | +2M | +356.65% | 2025-09-30 |
| Morgan Stanley | $5,234.00 | 1.43% | 1.49M | +655,642 | +78.48% | 2025-09-30 |
| Two Sigma Advisers, Lp | $5,014.00 | 1.37% | 1.43M | +1M | +1,005.57% | 2025-09-30 |
| Susquehanna International Group, Llp | $4,823.00 | 1.32% | 1.37M | -245,565 | -15.16% | 2025-09-30 |
| Citadel Advisors Llc | $4,500.00 | 1.23% | 1.28M | +758,553 | +144.91% | 2025-09-30 |